Acadia Pharmaceuticals (ACAD) Change in Accured Expenses (2010 - 2026)

Acadia Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $23.6 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 1135.29% year-over-year to $23.6 million; the TTM figure through Mar 2026 stood at $2.4 million (down 72.55% YoY), while the FY2025 annual figure was -$19.3 million, down 762.26% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $23.6 million, up from -$15.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $89.6 million in Q4 2023, with the low at -$37.4 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is $1.1 million (2024), against an average of $6.0 million.
• Peak annual rise in Change in Accured Expenses reached 3334.97% in 2023, while the deepest fall reached 2625.92% in 2023.
• Acadia Pharmaceuticals' Change in Accured Expenses stood at $2.6 million in 2022, then surged by 3334.97% to $89.6 million in 2023, then sank by 141.72% to -$37.4 million in 2024, then soared by 59.61% to -$15.1 million in 2025, then surged by 256.03% to $23.6 million in 2026.
• Business Quant data shows ACAD's Change in Accured Expenses at $23.6 million in Q1 2026, -$15.1 million in Q4 2025, and -$25.5 million in Q3 2025.